Shifting the lines against central nervous system disorders

« A disruptive technology, which can be applied in the treatment of numerous conditions »

> Press releases

Theranexus announces the nomination of Werner Rein as Chief Medical Officer (CMO)
29/08/2017
Download PDF File (93 Ko)

Theranexus annonce la publication d'un article scientifique évaluant le rôle des cellules non neuronales dans le traitement du système nerveux central
18/07/2017
Download PDF File (106 Ko)

Inclusion of the first patient in the phase II clinical study that aims to test THN102 in patients affected by narcolepsy
27/10/2016
Download PDF File (260 Ko)

Theranexus has obtained an orphan drug designation from the FDA for THN102 in the treatment of narcolepsy
04/10/2016
Download PDF File (428 Ko)

Theranexus and its partners receive support from the FUI (French Inter-ministry Fund) for their project, Cx-COG
20/09/2016
Download PDF File (149 Ko)

Theranexus reaches its primary endpoint in the proof of concept trial of THN102 in Excessive Daytime Sleepiness (EDS)
17/05/2016
Download PDF File (174 Ko)

Preclinical results published in the specialist medical journal Sleep, Phase II entry of THN102
30/03/2016
Download PDF File (111 Ko)

Inclusion of the first subjects in the efficacy study on the treatment of sleep disorders
19/10/2015
Download PDF File (556 Ko)

Success of phase 1 trial on the safety of a new treatment of narcolepsy and launch of efficacy studies
15/07/2015
Download PDF File (567 Ko)

Theranexus lève avec succès 3,6 M€ en amorçage
14/11/2014
Download PDF File (147 Ko)